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Abstract: Osteoporosis is a worldwide disease with a very high prevalence in humans older than 50. 
The main clinical consequence is bone fractures, which often lead to patient disability or even death. 
Currently, there are a number of commercial biomaterials used to treat osteoporotic bone fractures, 
but most of them have not been specifically designed for that purpose.  Simultaneously, many drug- or 
cell-loaded biomaterials have been proposed in research laboratories, but hardly any has received 
approval for commercial use. In order to analyze this scenario and propose alternatives to overcome 
this scenario, the Spanish and European Network of Excellence for the Prevention and Treatment of 
Osteoporotic Fractures "Ageing" was created. This network integrates three communities, e. g. 
clinicians, materials scientists and industrial advisors, tackling the same problem from three different 
points of view. Keeping in mind the premise "living longer, living better", this commentary is the result 







Please find the detaield answers to reviewers, indicating the changes introduced in the text. We 





Reviewer #1: General comments 
This is a summary of expert opinion on using biomaterials in the treatment of osteoporosis, 
especially fractures.  The perspective taken is novel and speaks directly to factors limiting 
application of biomaterials clinically. Interestingly, while regulatory concerns are discussed, part 
of the "blame" is on the research community which has not focused on developing materials 
specifically for osteoporosis and osteoporotic fractures.  The broad perspective on fraility and 
disability provided by this article will be helpful to the biomaterials community.  A key concept 
is early return to function, which is important because it dictates design criteria for biomaterials.   
Thank you for your positive comments 
The discussion of regulatory requirements will be helpful to the basic scientist, but the 
description of why so few devices have been approved could be improved.  Besides factors 
mentioned by the authors, key limitations often include lack of clear-cut, simple clinical 
endpoints for trials, and the cost-benefit analyses that companies perform to decide if there will 
ever be profit for a relatively small indication.  With regard to fracture, a limitation is that 
approval for a device is often for only one type or a very limited set of fractures (i.e., very narrow 
range of indications). 
Our intention was not to list all factors hindering innovation, but mentioning a few important 
ones. Nevertheless, the reviewer is perfectly correct in his/her statements. We propose the 
following modifications: 
We added the following text (page 24) : 
Since artificial joints may only prove their efficacy after 10 years, this requirement is particularly 
questionable and cost-intensive. Also, proving the efficacy of an implant may require multiple in 
vivo or clinical studies to support broad claims. For example, whereas it was possible in the past 
to only make one in vivo study for a “bone void filler, the authorities tend to require now more 
than one in vivo study. 
Further, we added (page 24): 
Currently, there is a trend towards the alignment of pharma and orthopedic product approvals. 
However, there is a major difference: whereas pharma products have generally a systemic 
action, orthopedic products have a local action (narrow range of indication). In other words, 
osteosynthesis plates or orthopedic implants are bone / joint specific, so each plate / implant 
requires a separate registration. The limited market size and increasingly large regulatory 
burdens are obviously important aspects / brakes in the decision processes occurring during 
product development. In fact, many R&D departments are nowadays focused on maintaining the 




Reviewer #2: This manuscript reviews possible solutions for preventing and treating 
osteoporosis.  It integrates the communications from clinicians, materials scientists and industrial 
advisors.  The review is very comprehensive and will serve as a good reference for r searchers 
working in the field.  There are a few grammar mistakes within the article.  It would be helpful if 
the authors proofread the manuscript prior to finalizing it. 
Here are a few examples: 
 
Page 2, Abstract, line 10, it should be ".such as clinicians, materials scientists and .." 
Page 4, 1st paragraph, line 1, it should be: ".may make it difficult for both the pre-.." 
Page 4, 2nd paragraph, line 1: it should be "..most of national health systems.." 
Page 4, 2nd paragraph, line 5: it should be "...the sustainability of some national health systems in 
the next a few years" 
Page 4, 4th paragraph, line 6, it should be ".from user needs to formal clinical outcome .." 
Page 5, 3rd bullet point, it should be "think about possible innovative treatments." 
 




 Reviewer #3: General comments: 
 
1) There are two clinical approaches in total hip replacement surgery. Hip prostheses can be fixed 
to bone with or without bone cements. The proportion of total hip replacements utilizing each 
type of fixation and the advantages and drawbacks of the approaches may be added. 
Following the reviewer suggestion, discussion about using bone cements in hip prostheses is 
added. We have added the following text (page 10) with the corresponding references (refs  47 to 
51 in the revised version): 
The dilemma in the choice of fixation method of prosthesis to bone (cemented or uncemeted ) is 
solved in favor of cemented prostheses ,taking into account the mean age of our patients ( more 
80 years ) more of 95% of arthroplasties are fixed to bone whit cement , because loss of bone 
mass in osteoporotic bone prevents good primary stability by press-fit of the uncemented 
prosthesis and less to achieve perfect bony integration of components , on the other hand the 
cemented prosthesis have less revision rates that uncemented for aseptic loosenig and excelent 
clinical results. Only in younger patients (less 70 years) with good bone quality and long life 
expectancy can be indicated uncemented arthroplasties. 
 
2) In section 3.1 the authors discuss the strategies used to increase the contact surface between 
bone and implant suggesting various approaches for implant designs related to improved 
osteointegration. The authors should also discuss the surface material properties of the materials 
related to their osseointegration. Surface roughness and wettability of the material are of crucial 
importance when trying to establish good bioactivity an osseointegration. 
The authors agree with the reviewer about the significance of roughness and wettabilty on the 
osteointegration of bone implants. We propose to add the following text (page 14) with the 
corresponding references references (refs  72 to 78 in the revised version): 
Another interesting topic is the role of surface roughness and wettability in implants 
osteointegration . This strategy has reached some degree of success especially in metallic 
implants for periodontal surgery.  For instance, modifications of microtopography in titanium 
implants have demonstrated enhanced osteointegration  . Prospective studies on implants with 
rough surfaces evidence very promising clinical results compared with those with smoother 
surfaces. In addition, the recent development of nanotechnology in biomaterials filed also allows 
the incorporation of nanofeatures onto implants surface. In this sense there are some studies that 
evidence the significance of nanotopography in the success of peri-implant bone formation , . 
Besides, the surface wettability is closely related with the surface micro/nanoroughness and also 
influences the osteoblast behavior. In principle, hydrophilic surfaces enhanced the osteoblast 
maturation , thus leading to better clinical results . 
3) The concept of implant coating is not discussed in the paper which may also be of interest for 
the readership. This reviewer recommends the following papers for further information: Bream et 
al. Acta Biomater 2013 Oct 22, Nguyen et al. Biomaterials. 2004; 25:865-76, Yang et al. 
Biomaterials. 2005 ;26:327-37, Surmenev et al. Acta Biomater. 2013 Nov 5. 
Following the reviewer’s comment, the following text (page 14) and the corresponding references  
(79 to 83 in the revised version) has been added to the manuscript: 
The coating of the surface of metallic implants has been successfully applied for decades to 
improve their bone-binding properties, with the cementless hip endoprosthesis and dental 
implants as the best-known examples. In particular, calcium phosphate coatings have been 
applied by various techniques, e.g. plasma spraying, sputtering techniques and sol-gel coating. 
Although an increased bone-binding ability has been found, a recent review points out that long-
term clinical studies lead to contradictory results. However, it may be envisioned that in 
osteoporotic bone, a surface modification of metallic implants, be it by calcium phosphate or by 
drug-releasing coatings will help to improve the clinical outcome, at least in the short-term 
performance when the primary stability is needed. 
 
4) Another important issue that could be added when describing the physical properties of the 
materials is a comparison of the materials' pore size and distribution as they greatly affect the 
ingrowth of new tissue and the degradation of the implanted material. 
In agreement whit the reviewer’s comment, the following paragraph has been added (page 16) 
together with the corresponding references (refs  105 to 109 in the revised version) 
In this sense, the design and development of porous ceramics have attracted much attention in the 
last years. Not only pore size, but also pore distribution can play a fundamental role in the bone 
regeneration, angiogenesis and implant degradation.  The incorporation of free form preparation 
methods such as 3D printing to the biomaterials field, allow the design of hierarchical pore 
structures to facilitate these processes. An interconnected macropore structure of 150- 1000 m 
allows cell colonization and enhances the diffusion rates to and from the center of a scaffold, as 
well as angiogenesis and bone ingrowth . Small pores allow phagocytic cells to adhere and resorb 
the scaffolds whereas larger pores encourage the invasion of new vessels and ingrowth of bone 
tissue . 
5) When discussing the properties of calcium silicate cements the authors may also mention 
injectable bone cements and  carriers for local drug delivery is nicely explained in the article. The 
authors may also add their beneficial influence on the mechanical properties of biological 
materials (Liu et al. Int Journal of Nanomedicine 2010, 5: 299 -313). 
The field of calcium silicate cements is not relevant for this review and such materials were not 
discussed in our paper. The report covers where appropriate the more relevant calcium phosphate 
cements. Regarding injectable calcium phosphate cements (assuming the referee refers to this 
group of biomaterials), the following statement has been added to the manuscript (page 12) to 
address the referee's comment (and 4 new relevant references (55 – 58) have been added): 
Indeed there is increasing research in the field of injectable calcium phosphate cements with 
recent efforts focusing on incorporating different additives including inorganic bioactive 
elements, e.g. bioactive glass, radiopacifiers, e.g. tantalum oxide or barium sulfate , 
biodegradable polymers to improve the injectability and modifications to incorporate antibiotic 
releasing capability. 
6) The usage of nanoparticles as carriers for local drug delivery is nicely explained in the article. 
The authors may also add their beneficial influence on the mechanical properties of biological 
materials (Liu et al. Int Journal of Nanomedicine 2010, 5: 299 -313). 
 
Following the reviewers comment the following text has been added to the manuscript (page 20), 
together with the corresponding references (148 -151 in the revised version) 
Note that in general, nanoparticles have not only been discussed as delivery agents, but that they 
can also be used to increase the mechanical strength after embedding into a polymeric matrix. 





The relevance of biomaterials to the prevention and 


























1 Envejecimiento: red de excelencia española y europea para la prevención y 
tratamiento local de fracturas osteoporóticas. MINECO. Spain. 
2
Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y 
Nanomedicina (CIBER-BBN), Madrid, Spain. 
3
Dpto. Química Inorgánica y Bioinorgánica. Universidad Complutense de Madrid. 
Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12. Madrid, Spain. 
4
University of Erlangen-Nuremberg, Institute of Biomaterials, 91058 Erlangen, 
Germany. 
5
RMS Fundation, CH-2544 Bettlach, Switzerland. 
6
Hospital del Mar-IMIM, Dept Internal Medicine, Barcelona, Universidad Autónoma de 
Barcelona, Spain. 
7
 University of Duisburg-Essen, Inorganic Chemistry and Center for Nanointegration 
Duisburg-Essen (CeNIDE), D-45117 Essen, Germany. 
8
Servicio Cirugia Ortopedica & Traumatologia, Hospital La Paz, IdiPAZ, Universidad 
Autonoma Madrid, Madrid 28046, Spain. 
9
Univ Zaragoza, Dept Surgery, E-50009 Zaragoza, Spain. 
10
Miguel Servet University Hospital, Dept Orthopaedic Surgery & Traumatology 
Zaragoza 50009, Spain. 
11
Inst. Bioengineering of Catalonia IBEC, Baldiri Reixac 15-20, Barcelona 08028, 
Spain. 
12
University Hospital Getafe, Division Geriatric Medicine, Madrid, Spain. 
   
 



















Osteoporosis is a worldwide disease with a very high prevalence in humans older than 
50. The main clinical consequence is bone fractures, which often lead to patient 
disability or even death. Currently, there are a number of commercial biomaterials used 
to treat osteoporotic bone fractures, but most of them have not been specifically 
designed for that purpose.  Simultaneously, many drug- or cell-loaded biomaterials have 
been proposed in research laboratories, but hardly any has received approval for 
commercial use. In order to analyze this scenario and propose alternatives to overcome 
this scenario, the Spanish and European Network of Excellence for the Prevention and 
Treatment of Osteoporotic Fractures “Ageing” was created. This network integrates 
three communities, e. g. clinicians, materials scientists and industrial advisors, tackling 
the same problem from three different points of view. Keeping in mind the premise 
“living longer, living better”, this commentary is the result of the thoughts, proposals 
and conclusions obtained after one year working in the framework of this network. 
 
1. Introduction and put in context.  
 
Ageing of the musculoskeletal system is a rapidly growing issue due to the 
demographics associated with ageing populations throughout the world. Its 
consequences on health are linked, among others, to osteoporosis, degenerative 
osteoarthritis and muscle deterioration or sarcopenia. These three elements interact to 
produce a picture of frailty, which often leads to bone fracture when a fall occurs, 
typically in people of advanced age. Fracture prevention, patient recovery, and 
avoidance of subsequent fractures constitute a challenge not yet resolved [1]. 
 
Bone weakening due to osteoporosis is far from finding a satisfactory solution. As a 
consequence of poor bone quality, surgical procedures performed to implant a device in 
weakened bone often lead to a clinical result that is worse than if such an intervention 
was performed on a young and strong bone. The risk of fracture increases exponentially 
with age, and the recovery process from a fracture is often slow, difficult and may lead 
to a disability or even to the death of the patient. Up to 25% of patients who suffer a 
femur fracture will die in the following year. Of those who survive, approximately half 
are totally or partially dependent [2]. Chronic pain, functional limitation, social 
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dependence, psychological disorders, reduced mental health score and social isolation 
converge on a serious deterioration in the quality of life.  
 
There are treatments available today to reduce the impact of bone fragility, but there is a 
lack of alternatives to restore bone strength. Moreover, there are no comprehensive 
treatments available for the whole damaged system, i.e. able to address the three factors 
of musculoskeletal unit fragility: bone, cartilage, and muscle. These three factors are 
both cause and consequence of the osteoporotic fracture [3].  
 
The economic aspects that surround this social and health issue are also of paramount 
importance [4], hence any action aimed at cost reduction should be seriously 
considered. It is worth mentioning that a surgical intervention for a hip prosthesis 
implantation has a health service cost of around €20,000, including direct, indirect and 
intangible costs [5]. For instance, the total current cost for hip fracture treatments with 
osteoporotic origin in the U.S. is 20.3 billion of U.S. dollars. This cost, far from 
diminishing, has experienced continuous growth throughout the 20th century and the 
first decade of the 21st century [6-8]. In fact, the total number of osteoporotic fractures 
in 1950 was 1.47 million and the projection for 2050 is around 6.3 million [9]. In the 
framework of the European Union, direct costs related to osteoporotic fractures in 2000 
were estimated to €31.7 billions [10]. Moreover, the increase in life expectancy of an 
increasingly ageing population leads to predict even more serious difficulties for the 
future.  
In the context of a socio-health problem such as osteoporosis, we may highlight 
three main agents involved in it: 
• The patient. All publications and web sites devoted to osteoporosis show that 
there is currently no satisfactory solution and that it remains as one of the major 
challenges for public health. This claim is based on significant mortality and disability 
(personal costs) and its relationship with the economic costs of the management, 
including treatment, of the patients (social costs). The patient, as a key player in the 
issue, is therefore still waiting for a satisfactory solution.  
• The therapeutic team. Once the fracture (whether of hip, spine, wrist, etc.) has 
occurred, the surgeon has only very few surgical solutions. In addition, other issues 
concerning general health (frailty, malnutrition, cognitive disorders, co-morbid 
conditions, polypharmacy, etc.) may make it difficult both the pre- and post-surgical 
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management of the patients. The reports issued by many of these professionals support 
the idea that enormous patient benefits could stem from preventive solutions.  
• The National Health System. In the European Union, most of national health 
systems are the purchasers of the prosthetic products and the defrayers of the 
intervention and hospitalization costs. Undoubtedly, the gradual ageing of society 
entails an increased number of osteoporotic patients, and this scenario could challenge 
the sustainability of some national health systems in the next a few years. 
Research into biomaterials has produced many variants of technologies, materials and 
physical forms intended to supplement or replace osteoporotic bone over the last 30 
years. However, very few of these have achieved broad application in either prevention 
or treatment of osteoporotic bone and its lesions. For those who are not directly 
involved with the commercialization of biomaterials it may be surprising that so little 
biomaterials research output reaches the operating theatre as part of a clinical treatment. 
However, there are many obstacles that biomaterials and their creators must overcome 
to prove safety and efficacy to the level required by the regulatory bodies in each 
country. Even where these are overcome it is far from certain that a biomaterial will be 
commercially exploited. Thus, the position today is that there are more limitations than 
opportunities for transferring biomaterials into clinical use, particularly in the 
management of poor bone quality. This opinion article will discuss some of the issues 
that account for the paucity of biomaterials in clinical use and also suggest what more 
might be done to encourage more viable clinical applications. 
 
To begin with, there are some mismatches between the aspirations of biomaterials 
researchers and (unmet) clinical needs. The goals of industry and academia are broadly 
similar to the surgeon community in wanting to improve clinical outcomes in a given 
clinical treatment. However, biomaterials are often developed by identifying the unmet 
clinical needs (note the terms used here such as “user needs” are as required in design 
control and quality systems for medical device design).  Even where the unmet needs 
are properly researched, their effective translation from user needs through to formal 
clinical outcome studies is quite uncommon. Even rarer is that a proper post-market 
surveillance is undertaken to ensure that any adverse outcomes are recognized as part of 




Considering this scenario, an interdisciplinary group of experts comprising clinicians, 
materials scientists and industrial advisors have constituted the Spanish and European 
Network of Excellence for the Prevention and Treatment of Osteoporotic Fractures 
“Ageing” (www.agening.net). This network shares and puts together information 
coming from different specialties and proposes possible solutions for the treatment of 
ageing diseases in bone, such as: 
 identify the most prevalent clinical problems and the most relevant 
clinical solutions, 
 analyze and discuss the role of drugs, implants, biomaterials and surgical 
techniques in such treatments, and 
 think about possible innovative treatments and even prevention. 
 
This article is the result of one year of discussions and thoughts, proposals and 
conclusions obtained in the “Ageing” framework. 
 
2. Osteoporosis. A clinician’s point of view. 
2.1. Significance of osteoporosis to frailty and disability.  
 
Last century a profound demographic change took place, the main consequence of 
which was a significant increase in the percentage of people older than 65, reaching 
levels of around 17%. In addition to this demographic change, a second transition 
occurred: the epidemiological transition, which produced a shift from the predominance 
of acute, single and communicable disease to a predominance of chronic, multiple and 
non-communicable diseases. As a consequence of these two complementary transitions 
the spectrum of diseases and the way of being ill has dramatically changed. If we finally 
take into account that life expectancy will slowly continue extending (EUROPOP 
forecasts support a modest increase in life expectancy around 5-7 years in the European 
Union countries for the next 50 years), the focus of health interventions should change 
from prolonging life to improve the quality of life. 
The most important surrogate of this quality of life is function. As functional status 
deteriorates, the quality of life gets worse. During the last century, as we prolonged life 
expectancy we were opening the door to the increased risk of disability with age, that 
would not be the case with a relatively young population. With agening, the loss of 
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functional reserve capacity put people at risk of developing disability, even under low-
power stressors. This is the explanation for the increase in the rates of disability that 
accompanied the extension of life expectancy during the last century (Fig. 1). But 
during the last 25 years, this tendency has changed in many countries. Although we do 
not know the causes explaining this drop in disability rates, this fact clearly shows that 
disability is an avoidable consequence of the ageing process and that if its main causes 




The fight against disability has several options, but probably the least attractive is to 
passively wait for the development of a disability. As previously stated, the main cause 
of disability is the loss of functional reserve capacity. But to successfully recover from 
disability a high level of that capacity is needed. In fact, only a small percentage 
(around 30%) of older people with incident disability is able to improve functionally 
during the first year [12]. This is why the main approach to improve the population 
functional status is the prevention of disability, instead of waiting to treat it. With this 
purpose in mind the concept of frailty has emerged as a relevant tool to detect people 
with the highest risk of developing a disability, both at short- and long-term (Fig. 2). 
Frailty is a state of increased vulnerability to stressors due to a decreased physiological 
reserve in multiple systems and a limited capacity to maintain homeostasis [13]. Its 
prevalence is around 10%, ranging from 1-3% for 65 years old people to more than 30% 
in people older than 80. It predicts the risk of suffering from multiple adverse outcomes, 
including death, hospitalization, disability and falls [14]. Detecting frailty is of clinical 
importance [15] as it has been shown that some therapeutic approaches, mainly based 
on physical exercise, are able to pull out patients from a frailty state, or at least delay 
frailty progression to full disability [16]. 
 
Within this framework, the approach to osteoporosis, as it is also the case for many 
other chronic conditions usually present in older people, should be focused on the 
prevention of the clinical pictures associated with frailty and disability. The most 
frequent of these conditions is the hip fracture. Taking into account that the most 
important risk factor for hip fracture is the risk of falls, the right way to manage these 
patients is based on a comprehensive assessment and management of falling patients. 
For this purpose the introduction of specialized Falls and Fracture Units is becoming the 
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standard approach to manage these patients, as recommended by different organizations, 
e.g. WHO, NICE, British Orthopaedic Association and the US Preventive Services Task 
Force. 
In this regard, the focus in these Units is to reinforce the idea of the continuum of care 
and a comprehensive approach to avoid or prevent disability in these patients, taking 
advantage of all available opportunities. One of these opportunities stems from the 
advances in the biomaterials used in the surgical materials used in those patients with 
hip fracture. These materials should have a double aim in the prevention of frailty and 
disability: firstly to allow an early mobilization of the patient after surgery and secondly 
to provide a quick and efficient restoration of bone and, as far as possible, of the 
musculoskeletal unit. 
 
2.2. Clinical aspects, prophylaxis and treatment of osteoporosis.  
 
Osteoporosis is a common disease with a rapidly increasing incidence associated to the 
population ageing [17,18]. The loss of bone and deterioration in its quality [19] induce 
decreased bone strength with the associated increase in fracture risk [20]. The main 
clinical consequences of the condition, therefore, are the fractures, associated with 
significant morbidity [21] and mortality [22]. 
Several factors contribute to an increased risk of osteoporosis and fracture. These risk 
factors have recently been structured in a decision algorithm, the FRAX
©
 tool, that 
allows the clinician to calculate the absolute risk of fracture in ten years for an 
individual patient [23]. This formula has been validated in a number of countries [24] 
and is available in several languages and for a large number of countries. Moreover and 
also partially integrated into FRAX, an important number of comorbidities have been 
identified that also influence fracture risk either by deteriorating bone or by increasing 
the propensity of patients to fall [25]. 
The clinical diagnosis of osteoporosis relies mainly in the measurement of bone mineral 
density by dual energy X-ray absorptiometry (DEXA) in several skeletal regions [26]. 
Other methods also calculate the mineral density by using ultrasound or quantified 
computerized tomography (QCT) scanners but their use in the general population is 
limited. These methods have in common the limitation of measuring only one of the 
determinants of bone strength, the amount of mineral or bone mass, but do not capture 
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the quality of the material. For this to be adequately done, laboratory testing of “ex 
vivo” specimens is required for measuring a broad spectrum of mechanical properties 
(brittleness, toughness, work to failure, etc.) [27]. Recently new techniques have been 
developed for the direct measurement of bone tissue strength [28, 29]. Biochemical 
markers of bone turnover, reflecting the rate of cell activity in the bone remodeling 
cycle have been also extensively developed and can predict the future fracture risk. [30] 
They also inform the clinician about the response to treatments [31]. Last but not least 
the simple detection in a routine radiograph or after a trauma permits the identification 
of fractures, the cornerstone of the disease and the responsible event for the morbidity 
and mortality associated with osteoporosis. Suffering a low-energy traumatic fracture 
(fragility fracture) is the ultimate demonstration of osteoporosis and constitutes per se a 
diagnostic marker.  
Osteoporosis prevention has two phases, primary prevention and secondary prevention. 
Primary prevention starts during intrauterine life, childhood and adolescence, given that 
this determines the development of a healthy strong skeleton in the adulthood. Even 
though genetic factors determine to a great extent how our bones are, the promotion of 
physical activity, adequate nutrition and the avoidance of negative factors for the 
normal bone development are extremely important.  
Secondary prevention starts once bone loss or bone fracture has occurred. Suffering a 
fracture is the most potent predictor of new fractures, in a progression of risk of a so 
called “fracture cascade”.  Two main groups of drugs are currently available for the 
management of the patients with osteoporosis: anticatabolics and anabolics [32]. The 
anticatabolic or antiresorptive agents suppress or attenuate the activity of the bone-
resorbing cells, the osteoclasts, hence stopping bone loss and increasing bone strength. 
On the other hand, anabolic agents are capable of inducing bone formation and, 
therefore, can revert in part the deterioration induced by the osteoporosis progression. 
The advances in this therapeutic field have been very significant over the last two 
decades since there are now several classes of drugs, including both chemical to 
biological entities, that decrease the risk of vertebral fracture and some also of non-
vertebral fractures (e.g. hip). The main development in treatment has been in 
postmenopausal osteoporosis in women although we have also treatments for 
glucocorticoid-induced osteoporosis [33,34] and osteoporosis in men [35]. In spite of 
the substantial body of clinical evidence, the management of this disease is still largely 
variable across different countries [36] and a considerable part of cases does not 
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respond to the treatment [37,38]. Whilst antiosteoporosis drugs have their side effects 
[39], these bone treatments have shown other health benefits such as cancer reduction in 
some instances [40] and also a decrease of the overall mortality [41]. In summary, there 
are now some effective tools that enable detection, diagnosis and treatment of 
osteoporosis to combat the progression of this metabolic disease, resulting from agening 
societies worldwide. 
 
2.3. Surgical treatment of osteoporotic fractures. 
 
Osteoporotic bone has special morphological and biological characteristics. Fracture 
healing depends mainly on the mechanical stability at the fracture site and the biological 
process of bone repair. Osteoporosis entails a decreased bone mass and an altered bone 
structure, leading to a lowered mechanical strength. So, osteoporotic fractures are often 
severely comminuted, especially in trabecular bone areas. Fracture comminution and 
trabecular collapse not only result in bone defects with impaired fracture stability, but 
also make anatomical reduction and surgical reconstruction difficult. Biologically, the 
mesenchymal stem cells (MSCs) of osteoporotic bone have less capacity to differentiate 
into osteoblasts than those of healthy bone, possibly due to impaired osteoinductive 
signals and/or lower expression of bone morphogenetic protein-2 (BMP-2). A decreased 
angiogenetic capacity at the fracture site is also common in osteoporotic bone [42]. 
Fracture fixation planning is determined by the special mechanical conditions of 
osteoporotic bone. It has to be noted that even in normal everyday activity, the loads 
supported by bones and joints are both large and dynamic, changing in both magnitude 
and direction with every step the patient makes. While implant failure is potentially a 
risk, less rigid fixation devices such as intramedullary nails, bridge plates and tension 
band constructs are preferred for minimizing bone-implant interface stress and the 
concomitant risk of bone failure. In compromised bone, improved screw holding power 
is essential to prevent screw pullout and/or migration and to minimize implant loading. 
Moreover, comminution makes fracture reduction more difficult, requiring the use of 
autologous bone grafts or biomaterials to fill bone defects and to augment bone 
fragments. It is therefore possible by combining implants and biomaterials to achieve 
sufficient overall assembly stability and fracture healing. Less load-resistant materials, 
even with bioactive capacity, may be used in the upper limb fractures. However, spine 
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and lower limb fractures require the use of inert biomaterials with greater load-bearing 
capacity, although calcium phosphate cements may be occasionally used. 
The most common osteoporotic fractures involve the spine, the hip and the distal radius. 
Surgical treatment of these fractures has changed in recent years. The distal radius 
fracture is known as “sentinel fracture” because it is the first warning sign of 
osteoporosis. We now know that surgical treatment of distal radial fractures, particularly 
by plates through palmar or dorsal approaches, does better than conservative treatment 
[43]. Severe comminution and bone fragment collapse are often present, requiring the 
use of biomaterials to fill bone defects, achieve fracture stability and promote bone 
union.  
Spine fracture is the most frequent osteoporotic fracture. Early diagnosis and medical 
treatment with anabolic drugs are essential to increase bone strength and prevent the so-
called “fracture cascade”. Vertebroplasty and kyphoplasty as minimal-invasive 
techniques show excellent results on quality of life, pain relief and functional recovery 
both short and long term [44]. More importantly, Edidin et al. [45] showed that the 
mortality of patients suffering from a vertebral bone fracture was significantly reduced 
when their fractures were treated by vertebroplasty or kyphoplasty. 
Treatment of hip fractures varies according to their anatomical location and 
classification. These are divided according to anatomically defined region: Intracapsular 
neck, extracapsular neck, pertrochanteric, intertrochanteric and subtrochanteric. 
Intracapsular fractures (see figure 3) have biological problems due to the loss of blood 
supply to the proximal fragment. Osteosynthesis is only indicated for undisplaced 
Garden I and II type intracapsular fractures in patients younger than 70 years. Total or 
partial hip arthroplasty, depending on the patient age, is the preferred technique for the 
displaced grades (Garden III and IV) fractures [46]. The dilemma in the choice of 
fixation method of prosthesis to bone (cemented or uncemeted ) is solved in favor of 
cemented prostheses ,taking into account the mean age of our patients ( more 80 years ) 
more of 95% of arthroplasties are fixed to bone whit cement , because loss of bone mass 
in osteoporotic bone prevents good primary stability by press-fit of the uncemented 
prosthesis and less to achieve perfect bony integration of components , on the other 
hand the cemented prosthesis have less revision rates that uncemented for aseptic 
loosenig and excelent clinical results. Only in younger patients (less 70 years) with 
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good bone quality and long life expectancy can be indicated uncemented arthroplasties 
[47-51]
The sliding hip screw, a device used in the treatment of trochanteric fractures, has been 
to some extent replaced over the years by intramedullary nails with a sliding cephalic 
screw. These are often made from titanium alloy and may feature reduced diameter and 
length to enable implantation by minimally invasive surgery [52]. The key determinants 
for good outcome are the correct placement of the cephalic screw and good anatomical 
fracture reduction. If a large posteromedial comminution is present, the bone defect can 
be augmented with a bone substitute such as a calcium phosphate cement. In cases of 
severe osteoporosis, bone structure of the femoral head can be strengthened by injecting 
PMMA cement through the cephalic screw, a technique known as augmentation, which 
prevents the cut-out.  
The challenge for the future will be the development of bioactive biomaterials that 
combine load bearing, interconnected porosity and the ability to be loaded with biologic 
factors that promote fracture healing.  
3. Osteoporosis. A materials scientist’s point of view.    
       
In an osteoporotic scenario, the paucity of bone and the decreased osteoblastic function 
result in an impaired response to implants compared with healthy bones. As mentioned 
in previous sections, this evidence is often observed by orthopedic surgeons in their 
daily practice of fracture reduction in osteoporotic patients. The experience of 
clinicians, outlined in section 2, teaches us that the primary issue with these patients is 
that they suffer from fractures that require some form of fixation, and the osteosynthesis 
elements such as plates, screws, nails, etc. are difficult to fix in low-quality bone. 
Besides, other scenarios different of fractures also affect the biomaterials performance 
in osteoporotic patients. For instance, the response of osteoporotic bone to endosseous 
implants, such as stems of total joint prostheses or endosseous dental implants, is also 
strongly impaired. In these cases, the implant failure is due to the poor biological 
fixation, which is consequence of an insufficient osteogenesis around the implant [53]. 
Despite of these evidences, there are no clinically approved biomaterials specifically 
tailored for application in osteoporotic bones. Certainly, there are some examples of 
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medical devices for osteosynthesis with special designs, but they are made of the same 
biomaterials than the conventional ones, such as titanium alloys, cobalt alloys or 
stainless steel.  
Attempting to reduce osteoporotic fractures, two classes of biomaterials are mainly 
used: metallic implants and cements. Their function is slightly different: whereas 
metallic implants are used as primary fixation devices, cements are mainly used as 
reinforcement of the metallic hardware. However, cements are also used as stand-alone 
devices, for example for bone augmentation procedures (injection of the cement into 
osteoporotic bone) [54]. Indeed there is increasing research in the field of injectable 
calcium phosphate cements with recent efforts focusing on incorporating different 
additives including inorganic bioactive elements, e.g. bioactive glass [55], 
radiopacifiers, e.g. tantalum oxide or barium sulfate [56], biodegradable polymers to 
improve the injectability [57]and modifications to incorporate antibiotic releasing 
capability [58]. Another difference between metallic implants and cements is the way 
they are adapted for osteoporosis-related indications. As mentioned above, metallic 
biomaterials are the same as those used in non-osteoporotic patients, but the implant 
shape is modified to accommodate osteoporosis-specific requirements. Sometimes, even 
new implants are created. For cements, the accent is set on a change of composition to 
obtain specific properties such as constant viscosity or high radiopacity. In addition, 
bioactive and/or resorbable ceramics such as calcium phosphates or bioactive glasses 
can be used to fill voids, thus avoiding the harvest of autogenous bone from the iliac 
crest.  
Besides the osteoporotic fractures reduction, biomaterials science also faces the quest of 
the impaired osteointegration of permanent endosseous implants.  The osteointegration 
in these cases is seriously affected, mainly due to the decreased osteoblast activity. An 
osteoporotic environment strongly affects the primary (short-term) stability of the 
implant, because the quality of the host bone is significantly decreased. Moreover, 
biological stability (early and long-term) is also impaired, as it requires deposition of 
newly formed bone in intimate contact with the implant [59]. Since this process 
involves the balanced action of osteogenic and bone resorbing cells, osteoporosis often 
has a poor prognosis and delayed healing and osteointegration with endosseous 
implants. However, similarly to devices for fracture fixation purposes, the research 
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efforts do not comprise the preparation of new metal alloys specifically intended to 
fabricate endosseous implants for osteoporotic patients [60].  
On the contrary, research on bioceramics (even playing a minor role compared with 
metals in the treatment of osteoporosis) envisions this scenario in a different way and 
often deals with the specific case of osteoporotic bone. In this sense, calcium 
phosphates bioceramics [61, 62] and SiO2 based mesoporous materials have been 
widely proposed as potential local antiosteoporotic drugs delivery systems [63], when 
used for void fillers in fracture fixation, bone grafting or augmentation.  
Combinations of biomaterials with cellular therapy and local drug delivery are of 
enormous interest because of the great opportunities that they offer to this problem [64-
66]. However, the technical and biological problems of the cells or materials to be used 
are important. These include (1) the limited cell viability; (2) the transient mechanical 
properties of the materials once implanted until they are substituted by regenerated 
bone; and (3) the biological integration at the specific bone site where they are 
implanted. To solve these problems, in vitro and in vivo tests should be performed in 
experimental conditions that mimic as much as possible the most prevalent situations 
associated with bone pathologies: estrogens depletion, diabetes mellitus, ageing, and 
treatment with glucocorticoids. To progress in this area, standard procedures to collect, 
manipulate and store mesenchymal osteoprogenitors (such as the bone marrow) should 
be defined. Thereafter, it would be possible to start considering the fabrication of a 
medical device following criteria accepted by national and international regulatory 
agencies for on-demand administration.  
 
3.1. Metallic implants 
Since osteoporotic bone is much more fragile than healthy bone, metallic implants used 
to treat osteoporotic bone fractures have to be designed differently. One strategy 
consists in increasing the contact surface area between bone and implant. This can be 
done by increasing the diameter of osteosynthesis screws [67]. Another approach is to 
use locked osteosynthesis plates [68]. In the latter case, plate loosening is only possible 
if all screws get loose simultaneously. This is in large contrast with unlocked plates 
whose fixation onto the bone relies on the compressive action of screws. A third 
approach consists in designing completely new implants, for example expandable 
spacers for vertebral height restoration (e.g. “VBS” (DePuy Synthes), “Spinejack 
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Vexim” (Vexim), “Kiva” (Benvenue Medical)) or cannulated screws (e.g. “Matrix 
Spine System” (Depuy Synthes)) to permit cement injection through the screw [69]. The 
cement injection through the screws (figures 4 and 5) gets an increase in the resistance 
of the fractured vertebral body and avoids the pull-out of screws in osteoporotic spine  
[70,71].  
Another interesting topic is the role of surface roughness and wettability in implants 
osteointegration [72]. This strategy has reached some degree of success especially in 
metallic implants for periodontal surgery. For instance, modifications of 
microtopography in titanium implants have demonstrated enhanced osteointegration 
[73]. Prospective studies on implants with rough surfaces evidence very promising 
clinical results compared with those with smoother surfaces [74]. In addition, the recent 
development of nanotechnology in biomaterials filed also allows the incorporation of 
nanofeatures onto implants surface. In this sense there are some studies that evidence 
the significance of nanotopography in the success of peri-implant bone formation 
[75,76]. Besides, the surface wettability is closely related with the surface 
micro/nanoroughness and also influences the osteoblast behavior. In principle, 
hydrophilic surfaces enhanced the osteoblast maturation [77], thus leading to better 
clinical results [78]. 
The coating of the surface of metallic implants has been successfully applied for 
decades to improve their bone-binding properties, with the cementless hip 
endoprosthesis and dental implants as the best-known examples. In particular, calcium 
phosphate coatings have been applied by various techniques, e.g. plasma spraying, 
sputtering techniques and sol-gel coating [79-82]. Although an increased bone-binding 
ability has been found, a recent review points out that long-term clinical studies lead to 
contradictory results [83]. However, it may be envisioned that in osteoporotic bone, a 
surface modification of metallic implants, be it by calcium phosphate or by drug-
releasing coatings will help to improve the clinical outcome, at least in the short-term 




Polymethylmethacrylate (PMMA) cement is the material of choice for the 
reinforcement of metallic implant fixation or osteoporotic bone due to its high 
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mechanical properties and low cost. However, PMMA cement has very important 
drawbacks such as monomer toxicity [84], risk of bone necrosis due to a highly 
exothermic setting reaction [85], absence of biodegradation that may lead to fatigue 
failure [86] , or too high material stiffness that may increase the fracture risk of vertebra 
adjacent to PMMA-reinforced vertebra [87]. As a result, various cements have been 
proposed to replace PMMA cement, but their success remains very limited due to 
toxicity, regulatory, price, or mechanical issues. For example, a few years ago the 
company “Orthovita” proposed a few years ago a dual paste cement called “Cortoss”. 
This cement is inspired from the composition of dental cement i.e. it consists of a matrix 
of Bis-GMA (2,2-bis [4-(2-hydroxymethacryloxypropyl)phenyl] propane), Bis-EMA 
(2,2-bis [4-(2-methacryloxyethoxy)] phenyl propane), and TEGDMA (triethylene glycol 
dimethacrylate) and is reinforced with bioactive glass particles [88]. “Cortoss” presents 
better handling, higher mechanical properties, and lower toxicity than PMMA cements. 
Unfortunately, it has a limited success, possibly due to price issues (higher production 
costs than PMMA cements). More recently, a silicone cement called “VK100” was 
proposed by the company “BonWRX”. This dual paste cement contains dimethyl 
methylvinyl siloxanes (87 %), barium sulfate powder (14 %), and a platinum catalyst 
(15 ppm as metal) in the first component, and dimethyl methylvinyl siloxanes (78 %), 
barium sulfate powder (15 %), and a methylhydrogensiloxane cross-linker (7 %) in the 
second component. Unfortunately, preliminary results for bone augmentation 
applications (“elastoplasty”) are very poor with more than 60% leakage (cement 
flowing outside the targeted location, e.g. into the spinal canal) and pulmonary 
embolism [89]. The too slow setting reaction was also mentioned. 
Considering the poor biological properties of polymer cements, quite a few ceramic 
cements have been proposed for bone augmentation procedures. Interesting candidates 
have been calcium phosphate cements (CPCs), but the results have been rather 
disappointing [90-93]. One main issue is the CPCs poor mechanical (shear stress) 
properties. Thus, CPCs can at most be used in load-sharing sites. Also, several deaths 
have been reported after the use of “Norian XR” CPC [94,95], suggesting some 
biocompatibility issues of CPCs in spinal applications. Higher mechanical properties 
were achieved with a calcium aluminate cement (“Xeraspine” from “Doxa AB”), but 
the results were not very good either [96]. The last ceramic cement that should be 
mentioned here is Plaster of Paris (= calcium sulfate hemihydrate). This material readily 
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dissolves in vivo due to its comparatively high solubility (i.e. without the help of 
osteoclasts), but nevertheless has been proposed for bone augmentation [97,98] and 
bone void filling applications, for example for the filling of the “Kiva” device. Besides 
bone augmentation, ceramic cements have also been used for screw augmentation [99-
102]. Some results are very promising [103,104], but more data are needed to assess the 
long-term success of this approach. 
 
3.3. Bioceramics for bone tissue regeneration 
Altogether, calcium phosphate ceramics and related compounds, i.e. calcium phosphate 
cements, bioglasses and calcium sulfate cements, represent the most important class of 
biomaterials for bone regeneration. Different types of calcium phosphate ceramics, 
glass-ceramics and glasses are currently being used and further developed for bone 
reconstruction and repair. In the present section the most prominent inorganic systems 
and, where appropriate, their composites in combination with polymers are described 
highlighting effects of ion release to induce osteogenesis and angiogenesis both 
functions required for effective bone tissue regeneration. In this sense, the design and 
development of porous ceramics have attracted much attention in the last years. Not 
only pore size, but also pore distribution can play a fundamental role in the bone 
regeneration, angiogenesis and implant degradation [105].  The incorporation of free 
form preparation methods such as 3D printing to the biomaterials field, allow the design 
of hierarchical pore structures to facilitate these processes [106]. An interconnected 
macropore structure of 150- 1000 m allows cell colonization and enhances the 
diffusion rates to and from the center of a scaffold, as well as angiogenesis and bone 
ingrowth [107,108]. Small pores allow phagocytic cells to adhere and resorb the 
scaffolds whereas larger pores encourage the invasion of new vessels and ingrowth of 
bone tissue [109]. 
 
 
3.3.1. Calcium phosphates  
  Calcium phosphate constitutes the inorganic mineral phase in mammalian bone and 
teeth. Therefore it is well known to the body and biocompatible by all current standards 
[110-112]. The calcium phosphate mineral in bone consists of nanocrystalline platelets 
of biological apatite, which chemically is a hydroxyapatite with ionic substitutions, 
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mainly carbonate [113]. A number of synthetic calcium phosphate ceramics are on the 
market as bone substitution material, with hydroxyapatite, Ca5(PO4)3OH (HAP), and -
tricalcium phosphate, -Ca3(PO4)2 (-TCP) and combinations of them ("biphasic 
calcium phosphate"; BCP) being the most prominent ones. They are available in 
different morphologies (typically as solid or porous blocks or as granules with different 
particle size) and with different origin (fully synthetic or derived from biological 
sources like animal bone or chemically transformed calcareous algae) [114]. In general, 
they are well accepted by the body, but as ceramics they are brittle by nature and 
therefore not able to withstand the mechanical challenge in a larger defect. With time, 
newly formed bone grows onto and into calcium phosphate ceramics and finally leads to 
a stable osteointegration [115]. The resorption of calcium phosphate ceramics typically 
involves acidic dissolution by osteoclasts [116,117].   
 
 
3.3.2. Bioactive glasses. 
Among all bioceramics, glasses have a special position due to their ability to rapidly 
release different ions, but also to strongly bind to bone through the formation of an 
apatite-like phase in the bone-implant interface (“bioactivity”). Depending on their 
chemical composition, bioactive glasses can be resorbed and their degradation 
byproducts can stimulate the osteogenic pathways in mesenchymal stem cells present at 
the fracture location. Indeed, the tailored effect of dissolution products from bioactive 
glasses on cellular responses, e.g. to upregulate the expression of genes controlling 
osteogenesis and to enhance vascular endothelial growth factor (VEGF) secretion in 
vitro to induce vascularization, are attractive qualities of bioactive glasses (and their 
composites) in the context of bone regeneration strategies [118]. For instance, the effect 
of silicate ions was recently investigated in relation to proliferation, osteogenic 
differentiation and cell signaling pathways of bone marrow stromal cells [119]. It has 
also been shown that cells where the calcium sensing receptor (CaSR) is present, such 
as mesenchymal stem cells and endothelial cells, respond to specific calcium 
concentrations in the environment by migrating, proliferating, and differentiating, 
expressing alkaline phosphatase and collagen 1 and mineralizing, and forming tubules 
respectively [120]. Therefore, it is hypothesized that any biomaterial with the 
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appropriate calcium-releasing capacity would be a good candidate for bone regeneration 
where angiogenesis is necessary. 
Typical silicate-based compositions such as “45S5” (wt.%: 45 SiO2, 24.5 Na2O, 24.5 
CaO, 6 P2O5) are characterized by a high surface bioactivity enabling strong bonding to 
bone tissue [121,122] leading also to stimulating effects on osteogenesis [123] and 
angiogenesis [124]. Starting with the classic “45S5 Bioglass®” composition [121], a 
great number of silicate systems incorporating specific ions into the silicate network is 
continuously developed. The typical ions that are under investigation are magnesium, 
strontium, silver, iron, copper, boron, potassium, lithium, cobalt, fluoride and zinc 
[125]. At variance, absorbable calcium phosphate glasses are able to solubilize 
completely with degradation times ranging from days to years, depending on their 
chemical composition. The vitreous network of [PO4] tetrahedra is easily hydrolyzed. 
The chemical stability of these glasses can only be modified by including different 
metallic oxides, such as Al2O3, ZnO, Fe2O3, and TiO2, into the three dimensional 
vitreous network. TiO2 has proved to be very efficient, given its four valences that link 
to four phosphate tetrahedral [126]. The capacity of calcium phosphate glasses to 
promote cell adhesion [127] and to induce vessels formation at the site of implantation 
[128] can be interpreted in terms of ion release. 
 
Being of high relevance in the context of osteoporosis-combating materials, the effect of 
specific ions on bone-resorbing osteoclast cells must be considered. For example, some 
researchers investigated the addition of strontium ions into silicate glasses as an 
effective approach to develop improved bioactive glasses [129], considering the positive 
results achieved with strontium ranelate (SrR) applied as a drug to treat and prevent 
osteoporosis especially in post-menopausal women.  Dedicated in vivo studies to assess 
potential bone healing enhancement in osteoporotic bone by grafting with bioactive 
glasses are still scarce [130], indicating a need for future research to realistically 
consider bioactive glasses as osteoporosis combating substances. It is also important to 
note that specific morphologies of silicate bioactive glasses (and silica), e.g. with a 
mesoporous structure [131] are attractive systems which enable the incorporation of a 





3.4. Associations of biomaterials with biological entities: gene and 
cellular therapies.      
 
3.4.1. Perspectives of gene therapies for bone regeneration purposes. 
 
As there is clearly a need for rapid bone regeneration after a fracture in osteoporotic 
bone, people have wondered since decades how bone growth can be stimulated by 
adding osteogenic compounds to biomaterials. This has led systems with a local drug 
delivery, e.g. of bone morphogenetic proteins (BMPs) [132-134] or of angiogenic 
proteins like VEGF [135,136], e.g. from polymers or ceramics. The release typically 
consists of a burst in the first days or weeks. The preparation and incorporation of 
proteins into biomaterials are usually costly. Another approach is a local gene therapy, 
provided by suitable biomaterials in direct bone contact. Gene therapy involves the 
delivery of DNA which can induce the production of the encoded protein after uptake 
by cells (so-called "transfection"). To accomplish this goal, suitable carriers are needed 
as nucleic acids alone cannot penetrate the cell wall. Furthermore, they are subject to 
rapid biodegradation by nucleases in the body.  
Two types of carriers for nucleic acids are currently discussed: Viruses and 
nanoparticles. They can be taken up by cells, together with their cargo of DNA. Viral 
transporter systems have the advantage of a very high transfection efficiency, but 
concerns remain about possible side-effects [137-139]. Nanoparticles can be organic 
(like liposomes or polymeric nanoparticles) or inorganic in nature [140, 141]. Their 
efficiency is typically lower than that of viruses, but they have the advantage that they 
can be more easily controlled due to their non-biological nature. 
The advantage of such a local gene delivery is the comparatively easy way to produce 
DNA in mg-scale and the long-lasting action. In principle, all kinds of cells around such 
a DNA-releasing implant can take up nanoparticles and start to produce DNA. Thereby, 
proteins like BMPs or VEGF can be produced and delivered in vivo to induce bone 
growth and vascularization [142-146]. It was recently shown that it is possible to induce 
the production of BMP-7 and VEGF-A from a paste of DNA-functionalized calcium 
phosphate nanoparticles. Thereby, osteoconductivity (by calcium phosphate) and 
osteoinduction (by production of the proteins around the implantation site) were 
combined [147]. Figure 6 shows an SEM-image of DNA-carrying calcium phosphate 
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nanoparticles. Note that in general, nanoparticles have not only been discussed as 
delivery agents, but that they can also be used to increase the mechanical strength after 
embedding into a polymeric matrix (see, e.g., ref [148]). This follows the concept of a 
biomimetic hierarchically structured material, mimicking bone itself [149-151]. 
 
Another option within the framework of gene therapy is the silencing of selected genes 
by administration of small-interfering RNA (siRNA). As such, the production of 
proteins which, e.g., inhibit bone growth or vascularization, can be down-regulated. 
This is called gene silencing, another highly promising method within the framework of 
gene therapy [152]. Again, suitable carriers like nanoparticles are necessary [153-155]. 
They have been successfully tested, e.g. to down-regulate inflammatory genes [156] or 
osteopontin and osteocalcin in osteoblasts [157]. A transfection by nanoparticles is 
always temporary, i.e. after a few weeks or months (depending on the release kinetics 
from the scaffold), it ceases, ideally after completed bone healing. This adds to the 
confidence after application in a bone defect. 
If osteoporotic bone shall be subjected to gene therapy to improve its strength, it would 
probably involve a local delivery of a nanoparticle-based system which carries suitable 
DNA. It is conceivable that this might work as a prevention of later fracture. 
 
3.4.2. Perspectives in the use of cell therapy in the reconstruction of 
osteoporotic bone.  
Recent developments of biomaterials largely reviewed in this paper converge on the 
needs of biological enhancement of biomaterials fostering osteoinduction and 
osteogenesis to support and augment bone healing after osteoporotic fractures. Indeed, 
the reconstruction of osteoporotic bone yields significant difficulties with the solutions 
available today. The osteoporotic bone, currently defined by its decreased quality (not 
quantity) leading to a mechanically incompetent biological material [158] manifests 
itself by the so-called osteoporosis-related fractures. Immediate consequences are bone 
collapse in metaphyseal compression fractures with bone defects and joint malfunction, 
comminution and delayed union or non-union after diaphyseal low energy fractures 
with thin cortices, or periprosthetic complex fractures on sclerotic bone surrounding 
implants. These problematic fractures seldom heal, restricting patient mobility and 
eventually leading to bed-ridden patients or even death. Therefore, therapeutic targets 
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can be defined, where advances in biomaterials are strongly needed. Basically, it has 
become clear that a biological problem is underlying this brittle, non-resistant bone. 
Frequently underestimated, biological insufficiency leads to significant bone healing 
problems. 
While some osteoinductive effect is observed with various biomaterials, osteogenesis is 
required to obtain satisfactory bone repair and directly relies on osteoprogenitors and 
derived osseous cell lines [159]. Yet the number of osteoprogenitors available in the 
surroundings of a fracture is unclear and unpredictable. Furthermore, the number of 
available progenitors seriously decreases with age, and estimates of stromal cells in the 
bone marrow drop to one eighth from young adulthood to old age. Consequently, 
elderly patients with osteoporosis who are more prone to fractures are associated with 
limited biological capabilities to heal bone. In that context, it is interesting to use a cell-
based therapy. However, despite significant advances in this field, efforts are hampered 
by various constraints: (i) the large number of in vivo and in vitro studies that are 
required in a pre-clinical stage, (ii) the safety and efficacy issues, and finally (iii) the 
regulatory and legal constraints.  
Three main cellular therapy strategies have been developed and translated into bone 
regenerative clinical solutions [160]. Mesenchymal stem cells (MSCs) from fresh, 
concentrated autologous bone marrow have been widely used to enhance bone healing 
at non-unions [161], usually in adults at an early age. Only a slight improvement of 
biological regenerative potential can be expected when 1000-1400 MSCs are obtained 
per 2 mL bone marrow aspirate in young patients with an aim of injecting more than 
55000 MSCs per injury. This autologous treatment allows for augmentation of surgical 
treatment without the consideration of introducing a cell-based medication into the 
patient, avoiding significant legal barriers when the whole process occurs during 
surgery.  
To further increase the biological regenerative potential, an expansion of bone marrow 
MSCs from the patient may lead to millions of MSCs within a few weeks. Although this 
manipulation transforms the cell product into an Advanced Therapy Medicinal Product 
(ATMP) that requires fabrication in certified GMP facilities (under Good 
Manufacturing Practices), proposals are being developed currently through clinical 
trials. A major barrier to the use of this solution today with elderly and osteoporotic 
patients is the limited amount of stromal cells in the bone marrow progenitor pool. 
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Other sources of MSCs face similar problems in elderly patients and the osteogenic line 
proliferation and differentiation may be further limited. Allogeneic expanded cells 
would be an ideal solution but safety and efficacy remains unproven and significant 
problems do not hold a clear solution. 
A third strategy under development involves MSC expansion on biomaterials. If an 
appropriate combination of biomaterial, cell dosage and stimulating molecules was 
found, structural and biological potential would facilitate and adequate bone substitute 
through tissue engineering closer to real bone. Only a few publications address clinical 
cases treated with this strategy [162], and in the autologous design, it is far from 
application in osteoporotic patients.  
Major issues remain to be solved before these advancements can be solidly applied into 
clinical trials in elderly patients with osteoporotic fractures or complications. Many 
questions are unclear about the adherence and osteogenic differentiation of 
osteoprogenitors on many biomaterials. Furthermore, it remains unproven whether 
osteoprogenitors expanded on biomaterials maintain the adherence and thus the 
location; or else, if the functional capabilities of these cells are kept after surgical 
implantation, in particular the osteogenic potential.  
However, even if serious barriers should be overcome, research lines are in place and 
the confirmed needs in these particular targets will probably transform in the coming 
years the way we understand the clinical potential of bone tissue engineering based on 
advanced biomaterials and cell therapy solutions. 
To conclude, biomaterials used for osteoporosis-related clinical indications are fairly 
traditional, including metals, polymers, and ceramics. Their design (shape, composition) 
is generally adapted to better accommodate osteoporosis-related requirements. Part of 
the gap between clinical biomaterials and academic research can be explained by 
increasingly stringent safety regulations, as well as cost pressures. This will be 
discussed in more details in the next sections. 
 
4. Biomaterials and osteoporosis. The industrial’s point of view. 
 The previous sections have shown that there is a great need to improve the treatment of 
osteoporotic patients before and after the occurrence of a bone fracture. Various routes 
for therapeutic progress have been highlighted, including tissue engineering, drug-
loaded bone graft substitutes, and gene therapy. Despite these needs and efforts, little 
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progress is seen clinically. In fact, the launch of BMP-loaded products a decade ago was 
the last important innovation. This impression is confirmed by the evolution of pre-
market approvals (PMA) issued by the FDA (Fig 7). A PMA is compulsory for any 
device that does not have its equivalent on the market. In other words, the most 
innovative products have to go through a PMA review process. Over the last 10 years, 
the number of PMAs accepted by the FDA has decreased dramatically. Specifically, 23 
PMAs were accepted from 2003 to 2007. This number dropped to 8 from 2008 to 2012. 
Simultaneously, there was a 50% increase of the 510k notifications, which are issued 
for products equivalent to other products already FDA approved. These two trends 
mean that companies in the US are shifting their efforts from innovations to incremental 
improvements of existing technologies. This situation in Europe is similar. 
Many aspects have contributed to this decrease in the number of innovations. The most 
obvious one is related to the laws regulating medical devices. Over the past decades, the 
European authorities have strengthened their directives, not only by asking more data 
per product, but also by transferring certain products into higher product classes. This is 
the case for joint prostheses that were class II products until March 2010, and which are 
now class III products. Also, new ISO standards are continuously approved, which 
means that more tests have to be done to apply for a CE marking. It is clear that ISO 
standards are not compulsory, but it is often easier to perform the study than to explain 
why it was not performed. This is particularly disturbing for tests that have been shown 
to present important weaknesses, such as ISO 10993-5 (Biological evaluation of 
medical devices - Part 5: Tests for in vitro cytotoxicity), or the so-called “bioactivity 
test” (ISO 23317; Implants for surgery -- In vitro evaluation for apatite-forming ability 
of implant materials). In both cases, false positives and false negatives can be found (for 
ISO 23317, see references [163] and [164]). The trend towards stricter regulations is not 
expected to stop soon. In fact, much stricter directives have been proposed following the 
recall of PIP breast implants and DePuy metal-on-metal hip prosthesis. These directives 
are currently awaiting approval. 
In 1985, the European parliament decided to harmonize the laws regulating medical 
devices within Europe to facilitate the transfer of goods. Directives were defined and 
implemented. Even though CE marked products can access the European market, other 
hurdles are still in place. For example, the French authorities ask companies to register 
their products prior to any reimbursement. In the US, the government decided a few 
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years ago to stop reimbursing vertebral bone augmentation procedures following the 
publication of two articles demonstrating an absence of significant effect between the 
treatment group and a “placebo” group [165, 166]. The fact that numerous publications 
have shown the limitations of these two studies has not changed the situation. In fact, 
medical device companies are increasingly asked to show the effectiveness of their 
product before reimbursement is issued. Since artificial joints may only prove their 
efficacy after 10 years, this requirement is particularly questionable and cost-intensive. 
Also, proving the efficacy of an implant may require multiple in vivo or clinical studies 
to support broad claims. For example, whereas it was possible in the past to only make 
one in vivo study for a “bone void filler, the authorities tend to require now more than 
one in vivo study. This is often very costly and may take years. Once a product is 
accepted for reimbursement, governments may decide on the product value. According 
to the French “Liste des Produits et Prestations” (LPP), a resorbable interference screw 
for ligament fixation is worth 234.16 Euros.  
Currently, there is a trend towards the alignment of pharma and orthopedic product 
approvals. However, there is a major difference: whereas pharma products have 
generally a systemic action, orthopedic products have a local action (narrow range of 
indication). In other words, osteosynthesis plates or orthopedic implants are bone / joint 
specific, so each plate / implant requires a separate registration. The limited market size 
and increasingly large regulatory burdens are obviously important aspects / brakes in 
the decision processes occurring during product development. In fact, many R&D 
departments are nowadays focused on maintaining the product portfolio and reducing 
the costs, rather than developing new products. 
Nowadays, governments are facing a dilemma: if they tighten the rules to obtain the CE 
mark of a new medical product, they restrict innovation, hence reducing chances to see 
new therapies; if they do not tighten the rules after the recent medical device scandals 
(PIP breast implants, DePuy metal-on-metal prosthesis), their electors might punish 
them at the next elections or even sue them as seen with the contaminated blood 
scandal. Currently, the former strategy is pursued worldwide, detrimentally to all 








Osteoporosis is a disease that has become a worldwide challenge and comprises clinical, 
social and economic issues. This is mainly due to the increase of life expectancy, so the 
society, the health systems and industry should be aware of this problem, as an ageing 
population will be more prone to osteoporosis.  
The main clinical consequences of osteoporosis are the fractures. The success of 
biomaterials for fracture fixation in osteoporotic patients, or simply for bone 
augmentation treatments, is impaired by the poor quality of bone and the decreased 
osteoblastic activity. In this sense, although there are a number of biomaterials to treat 
problems with bone in the market, they are not necessarily appropriate to address 
osteoporotic bone. Unsuccessful implantation can result in overpassing the line between 
frailty and disability in osteoporotic patients.   
Clinicians, biomaterials scientists and industrial advisors are making important efforts 
to improve current implants and their applications, as well as provide new alternatives. 
Compounds able to stimulate the bone regeneration such as calcium phosphates (both 
ceramics and cements), calcium sulfates or bioglasses are being widely considered, 
especially associated with local drug and/or gene delivery as well as with cell therapy.  
However, all these efforts only will be fruitful if these new biomaterials are 
successfully developed and commercialized. Currently, the level of commercial 
innovation remains well below expectations and the situation is only expected to worsen 
due to more stringent certification requirements and higher cost pressures. Thus, those 
that will play a major role in the prevention and treatment of osteoporotic conditions 
will most likely feature the following points: 
 
- A well-developed definition of unmet needs 
- It will most likely be indication-specific  
- It will enable quantifiable clinical benefits to be proven in level of evidence 
1 clinical studies 
- It will be reimbursable 
- A collaborative petition to agencies such as FDA could be helpful 
 
Consequently, more research is necessary, driven by the clinical demand, to solve this 
problem. The fact that the current situation is difficult to manage should not prevent us 
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to seek new solutions. For this purpose, a close cooperation between fundamental 
research, industrial research, clinical research and regulatory bodies is required for the 
future. This will not be available for free (i.e. without money), but will pay off in the 
long run for everybody 
In addition, the presence of new patients with new characteristics and new needs, 
mainly (but not exclusively) older people with frailty, should change not only the way 
to provide their management and treatment, but also the aims of the care and the way to 
assess the technological improvements. Regarding this last issue it should concern both 
the changes on how to organize the delivery of the care provided to these patients, the 
characteristics of the devices and its outcomes as well. This new model to assess the 
efficacy and effectiveness of the new technologies in the new patients should prompt a 
change in the rules of the regulatory agencies in order to adapt their procedures to the 
current needs of both the patients, the health systems and the industry, thus contributing 
to the well-being of the patients, the sustainability of the health systems and the 




The Spanish and European Network of Excellence for the Prevention and Treatment of 
Osteoporotic Fractures “Ageing” is financially supported by the Ministerio de 
Economía y Competitividad through the project CSO2010-11384-E. 
 
References 
1. Planell J A, Navarro M. Challenges of bone repair, in Bone Repair Biomaterials. 
Planell, Best, Lacroix and Merolli eds. 2009, CRC Press, Cambridge. 
2.  Streubel PN, Ricci WM, Wong A, Gardner MJ. Mortality after distal femur 
fractures in elderly patients. Clin Orthop Relat Res 2011; 469: 1188-96. 
3.  National Osteoporosis Foundation. http://www.nof.org  
4. Hoerger TJ, Downs KE, Lakshmanan MC, Lindrooth RC, Plouffe Jr L, Wendling 
B, et al. Healthcare use among U.S. women aged 45 and older: Total costs and 
costs for selected postmenopausal health risks. J Womens Health Gend Based 
Med 2007; 8: 1077-89. 
5. Rissanen P, Aro S, Sintonen H, Asikainen K, Slätis P, Paavolainen P. Costs and 
Cost-Effectiveness in Hip and Knee Replacements: A Prospective Study?. 
27 
 
International Journal of Technology Assessment in Health Care 1997; 13: 574-
588. 
6.  Day JC. Population projections of the United States by age, sex, race and 
Hispanic origin: 1995 to 2050. US Government Printing Office, Washington, DC. 
7.  Ray NF, Chan JK, Thamer M, Melton III LJ. Medical expenditures for the 
treatment of osteoporotic fractures in the United States in 1995: Report from the 
National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24-35. 
8.  Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic 
fractures. Bone 1994; 15: 377-86. 
9. Melton LJ. Hip fractures: a worldwide problem today and tomorrow. Bone 1993; 
14: 1-8. 
10. Kanis JA, Johnell O. Requeriments for DXA for the management of osteoporosis 
in Europe. Osteopor Int 2005; 16: 229-238. 
11. Manton KG, Gu X. Changes in the prevalence of chronic disability in the United 
States black and nonblack population above age 65 from 1982 to 1999. Proc Natl 
Acad Sci U S A. 2001; 98: 6354-9. 
12. Boyd CM, Landefeld CS, Counsell SR, Palmer RM, Fortinsky RH, Kresevic D et 
al. Recovery of activities of daily living in older adults after hospitalization for 
acute medical illness. J Am Geriatr Soc. 2008; 56: 2171-9. 
13. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. 
Lancet 2013; 381: 752-62. 
14. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al. 
Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 
2001; 56: M146–56. 
15. Rodríguez-Mañas L, Féart C, Mann G, Viña J, Chatterji S, Chodzko-Zajko W et 
al. Searching for an operational definition of frailty: a Delphi method based 
consensus statement: the frailty operative definition-consensus conference project. 
J Gerontol A Biol Sci Med Sci. 2013; 68: 62-7. 
16. Espeland MA, Gill TM, Guralnik J, Miller ME, Fielding R, Newman AB et al. 
Designing clinical trials of interventions for mobility disability: results from the 
lifestyle interventions and independence for elders pilot (LIFE-P) trial. J Gerontol 
A Biol Sci Med Sci. 2007; 62: 1237-43. 
28 
 
17. Felsenberg D, Silman AJ, Lunt M, Armbrecht G, Ismail AA, Finn JD et al. 
Incidence of vertebral fracture in europe: results from the European Prospective 
Osteoporosis Study (EPOS). Journal of bone and mineral research: the official 
journal of the American Society for Bone and Mineral Research 2002; 17: 716-24. 
18. Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgstrom F et al. 
Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 
2021: estimations from a disease model. Archives of osteoporosis 2011; 6: 179-
88. 
19. Seeman E, Delmas PD. Bone quality--the material and structural basis of bone 
strength and fragility. The New England journal of medicine 2006; 354: 2250-61. 
20. Consensus conference: Osteoporosis. JAMA: the journal of the American Medical 
Association 1984; 252: 799-802. 
21. Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ et al. 
Number and type of vertebral deformities: epidemiological characteristics and 
relation to back pain and height loss. European Vertebral Osteoporosis Study 
Group. Osteopor Int 1999; 9: 206-13. 
22. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK 
et al. Reduction of vertebral fracture risk in postmenopausal women with 
osteoporosis treated with raloxifene: results from a 3-year randomized clinical 
trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am 
Med Assoc 1999; 282: 637-45. 
23. Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD et al. 
Official Positions for FRAX(R) Bone Mineral Density and FRAX(R) 
simplification from Joint Official Positions Development Conference of the 
International Society for Clinical Densitometry and International Osteoporosis 
Foundation on FRAX(R). J Clin Densitom 2011; 14: 226-36. 
24. Gonzalez-Macias J, Marin F, Vila J, Diez-Perez A. Probability of fractures 
predicted by FRAX(R) and observed incidence in the Spanish ECOSAP Study 
cohort. Bone 2012; 50: 373-7. 
25. Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD et al. 
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal 
Study of Osteoporosis in Women (GLOW). Bone 2012; 50: 1288-93. 
29 
 
26. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA et al. Joint 
Official Positions of the International Society for Clinical Densitometry and 
International Osteoporosis Foundation on FRAX((R)). Executive Summary of the 
2010 Position Development Conference on Interpretation and use of FRAX(R) in 
clinical practice. J Clin Densitom 2011; 14: 171-80. 
27. Zioupos P, Hansen U, Currey JD. Microcracking damage and the fracture process 
in relation to strain rate in human cortical bone tensile failure. J Biomechanics 
2008; 41: 2932-9. 
28. Diez-Perez A, Guerri R, Nogues X, Caceres E, Pena MJ, Mellibovsky L et al. 
Microindentation for in vivo measurement of bone tissue mechanical properties in 
humans. J Bone Miner Res 2010; 25: 1877-85. 
29. Guerri-Fernandez RC, Nogues X, Quesada Gomez JM, Torres Del Pliego E, Puig 
L, Garcia-Giralt N et al. Microindentation for in vivo measurement of bone tissue 
material properties in atypical femoral fracture patients and controls. J Bone 
Miner Res 2013; 28: 162-8. 
30. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of 
bone turnover, endogenous hormones and the risk of fractures in postmenopausal 
women: the OFELY study. J Bone Miner Res 2000; 15: 1526-36. 
31. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A et al. 
Markers of bone turnover for the prediction of fracture risk and monitoring of 
osteoporosis treatment: a need for international reference standards. Osteoporos 
Int 2011; 22: 391-420. 
32. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. 
European guidance for the diagnosis and management of osteoporosis in 
postmenopausal women. Osteoporos Int 2013;24:23-57. 
33. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F et 
al. A framework for the development of guidelines for the management of 
glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23: 2257-76. 
34. Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A et al. 
Management of glucocorticoid-induced osteoporosis. Calcif Tiss Int 2012; 91: 
225-43. 
35. Kaufman JM, Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W et al. 
Treatment of osteoporosis in men. Bone 2013; 53: 134-144. 
30 
 
36. Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S et al. 
Regional differences in treatment for osteoporosis. The Global Longitudinal Study 
of Osteoporosis in Women (GLOW). Bone 2011; 49: 493-8. 
37. Diez-Perez A, Olmos JM, Nogues X, Sosa M, Diaz-Curiel M, Perez-Castrillon JL 
et al. Risk factors for prediction of inadequate response to antiresorptives. J Bone 
Miner Res 2012; 27: 817-24. 
38. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings 
SR et al. Treatment failure in osteoporosis. Osteoporos Int 2012; 23: 2769-2774. 
39. Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A, Felsenberg D et al. 
Adverse reactions and drug-drug interactions in the management of women with 
postmenopausal osteoporosis. Calcif Tiss Int 2011; 89: 91-104. 
40. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG. Reduced colon 
cancer incidence and mortality in postmenopausal women treated with an oral 
bisphosphonate--Danish National Register Based Cohort Study. Osteoporos Int 
2012; 23: 2693-701. 
41. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C 
et al. Zoledronic acid and clinical fractures and mortality after hip fracture. The 
New Eng Journal of Medicine 2007; 357: 1799-809. 
42. Kwong FN ,Harris MB Recent developments in the biology of fracture repair. J 
Am Acad Orthop Surg 2008;16:619-625. 
43. Diaz-Garcia RJ, Oda T, Shauver MJ, Chung KC A systematic review of outcomes 
and complications of treating unstable distal radius fractures in the elderly. J Hand 
Surg Am. 2011 May;36(5):824-35. 
44. Papanastassiou ID, Phillips FM, Van Meirhaeghe J, Berenson JR, Andersson GB, 
Chung G, et al .Comparing effects of kyphoplasty, vertebroplasty, and non-
surgical management in a systematic review of randomized and non-randomized 
controlled studies. Eur Spine J. 2012 ;21:1826-43. 
45. Edidin AA, Ong KL, Lau E, Kurtz SM. Mortality Risk for Operated and 
Nonoperated Vertebral Fracture Patients in the Medicare Population. J Bone 
Miner Res 2011,26; 1617-1626. 
46. Gao H, Liu Z, Xing D, Gong M. Which is the best alternative for displaced 
femoral neck fractures in the elderly?: A meta-analysis. Clin Orthop Relat Res. 
2012 ; 470:1782-91. 
31 
 
47.  Keating JF, Grant A, Masson M, Scott NW, Forbes JF. Randomized comparison 
of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. 
Treatment of displaced intracapsular hip fractures in healthy older patients. J Bone 
Joint Surg Am. 2006 ;88:249-60. 
48. Morshed S, Bozic KJ, Ries MD, Malchau H, Colford JM Jr. Comparison of 
cemented and uncemented fixation in total hip replacement: a meta-analysis. Acta 
Orthop. 2007;78:315-26. 
49. Yamada H, Yoshihara Y, Henmi O, Morita M, Shiromoto Y, Kawano T, Kanaji 
A, Ando K, Nakagawa M, Kosaki N, Fukaya E.Cementless total hip replacement: 
past, present, and future. J Orthop Sci. 2009 ;14:228-41. 
50. Parker MJ, Gurusamy KS, Azegami S.Arthroplasties (with and without bone 
cement) for proximal femoral fractures in adults. Cochrane Database Syst Rev. 
2010; 16:CD001706. 
51. Abdulkarim A, Ellanti P, Motterlini N, Fahey T, O'Byrne JM.Cemented versus 
uncemented fixation in total hip replacement: a systematic review and meta-
analysis of randomized controlled trials. Orthop Rev (Pavia). 2013 ;5:e8. 
52. Lorich DG, Geller DS, Nielson JH. Osteoporotic pertrochanteric hip fractures. 
Management and current controversies. J Bone Joint Surg Am 2004; 86:398- 410. 
53. Fini M, Giavaresi G, Torricelli P, Krajewski A, Ravaglioli A, Mattioli Belmonte 
M, et al. Biocompatibility and osteointergration in osteoporotic bone. J Bone Joint 
Surg Br 2001, 83:139-143. 
54. Heini PF, Berlemann U, KaufmanM, Lippuner K, Fankhauser C, Van Landuyt P. 
Augmentation of mechanical properties in osteoporotic vertebral bones – a 
biomechanical investigation of vertebroplasty efficacy with different bone 
cements. Eur Spine J. 2001, 10, 164-171. 
55. Yu L, Li Y, Zhao K, Tang Y, Cheng Z, Chen J, et al. A Novel Injectable Calcium 
Phosphate Cement-Bioactive Glass Composite for Bone Regeneration, PlOSOne 
(2013) DOI: 10.1371/journal.pone.0062570. 
32 
 
56. Hoekstra JWM, van den Beucken JJJP, Leeuwenburgh SCG, Bronkhorst EM, 
Meijer GJ, Jansen JA. Tantalum oxide and barium sulfate as radiopacifiers in 
injectable calcium phosphate-poly(lactic-co-glycolic acid) cements for monitoring 
in vivo degradation J Biomed Mater Res 2014; A102: 141-149. 
57.  Chen W, Zhou H, Weir MD, Tang M, Bao C, Xu HHK. Human Embryonic Stem 
Cell-Derived Mesenchymal Stem Cell Seeding on Calcium Phosphate Cement-
Chitosan-RGD Scaffold for Bone Repair, Tiss Eng Part A. 2013 ;19 :915-927. 
58. Vorndran E, Geffers M, Ewald A, Lemm M, Nies B, Gbureck U. Ready-to-use 
injectable calcium phosphate bone cement paste as drug carrier, Acta 
Biomaterialia 2013; 9: 9558–9567. 
59. Franchi M, Fini M, Giavaresi G, Ottani V. Peri-implant osteogenesis in health and 
osteoporosis. Micron 2005; 36:630-644. 
60. Fini M., Giavaresis G, Torricelli P, Borsari V, Giardino R, Nicolini A, et al. 
Osteoporosis and biomaterial osteointegration. Biomedicine & Pharmacotherapy 
2004; 58: 487-493. 
61. Verron E, Gauthier O, Janvier P, Pilet P, Lesouer J, Bujoli B, et al. In vivo bone 
augmentation in an osteoporotic environment using bisphosphonate-loaded 
calcium deficient apatite. Biomaterials 2010; 31: 7776-7784. 
62. Manzano M, Lozano D, Arcos D, Portal-Nuñez S, López C, Esbrit P, et al. 
Comparison of the osteoblastic activity conferred to si-doped hydroxyapatite 
scaffolds by different osteostatin coating. Acta Biomaterialia. 2011; 7: 3555-3562. 
63. Arcos D, Vallet-Regi M,. Bioceramics for drug delivery. Acta Materialia 
2013;61:890-911. 
64. Verron E, Bouler JM, Guicheux J. Controlling the biological function of calcium 
phosphate bone substitutes with drugs. Acta Biomaterialia 2012, 8:3541-3551. 
65. Trejo CG,  Lozano D, Manzano M, Doadrio JC, Salinas AJ, Dapia S, et al. The 
osteoinductive properties of mesoporous silicate coated with osteostatin in a rabbit 
femur cavity defect model. Biomaterials 2010; 31: 8564-8573. 
66. Manzano M, Vallet-Regí M. Revisiting bioceramics: bone regenerative and local 
drug delivery systems. Prog. Solid State Ch. 2012;40: 17-30. 
67. Chapman JR, Harrington RM, Lee KM, Anderson PA, Tencer AF, Kowalski D. 
Factors affecting the pullout strength of cancellous bone screws. Journal of 
Biomechanical Engineering 1996;118:391-398. 
33 
 
68. Frigg R, Frenk A, Wagner M. Biomechanics of plate osteosynthesis. Tech Orthop 
2007;22:203-8. 
69. McKoy BE, An YH. An injectable cementing screw for fixation in osteoporotic 
bone. J Biomed Mater Res 2000;53:216-20. 
70. Hu MH, Wu HT, Chang MC, Yu WK, Wang ST, Liu CL. 
Polymethylmethacrylate augmentation of the pedicle screw: the cement 
distribution in the vertebral body. Eur Spine J. 2011; 20:1281-8. 
71. Choma TJ, Pfeiffer FM, Swope RW, Hirner JP. Pedicle screw design and cement 
augmentation in osteoporotic vertebrae: effects of fenestrations and cement 
viscosity on fixation and extraction. Spine (Phila Pa 1976) 2012; 37:E1628-32. 
72. Gittens RA, Olivares-Navarrete R, Cheng A, Anderson DM, McLachlan T, 
Stephan I, et al. The roles of titanium surface micro/nanotopography and 
wettability on the differential response of human osteoblast lineage cells. Acta 
Biomaterialia 2013; 9:6268-77. 
73. Buser D, Schenk RK, Steinemann S, Fiorellini JP, Fox CH, Stich H. Influence of 
surface characteristics on bone integration of titanium implants – a 
histomorphometric study in miniature pigs. J Biomed Mater Res 1991; 25:889-
902. 
74. Cocharan DL, Jackson JM, Bernard JP, ten Bruggenkate CM, Buser D, Taylor 
TD, et al.A 5-year prospective multicenter study of early loaded titanium implants 
with a sandblasted and acid-etched surface. Int Oral Maxillofac Implants 2011; 
26:1324-32. 
75. Orsini G, Piattelli M, Scarano A Petrone G, Kenealy J, Piattelli A, et al. 
Randomized, controlled histologic and histomorphometric evaluation of implants 
with nanometer-scale calcium phosphate added to the dual acid-etched surace in 
the human posterior maxilla. J Periodontol 2007; 78:209-18. 
76. Collaert B, Wijnen L, De Bruyn H. A 2-year prospective study on immediate 
loading with fluoride-modified implants in the edentulous mandible. Clin Oral 
Implants Res 2011;22:1111-6. 
77. Park JH, Wasilewski CE, Almodovar N, Olivares-Navarrete R, Boyan BD, 
Tannenbaum R, et al. The responses to surface wettability gradientes induced by 
chitosan nanofilms on microtextured titanium mediated by specific integrin 
receptors. Biomaterials 2012; 33: 7386-93. 
34 
 
78. Bornstein MM, Wittneben JG, Bragger U, Buser D. Early loading at 21 days of 
non-submerged titanium implants with a chemically modified sandblasted and 
acid-etched surface. 3-year results of a prospective study in the posterior 
mandible. J Periodontol 2010;81:809-18. 
79. Nguyen HQ, Deporter DA, Pilliar RM, Valiquette N, Yakubovich R. The effect of 
sol-gel-formed calcium phosphate coatings on bone ingrowth and 
osteoconductivity of porous-surfaced Ti alloy implants. Biomaterials 
2004;25:865-76. 
80. Yang Y, Kim KH, Ong JL. A review on calcium phosphate coatings produced 
using a sputtering process - an alternative to plasma spraying. Biomaterials 
2005;26:327-37. 
81. Surmenev RA. A review of plasma-assisted methods for calcium phosphate-based 
coatings fabrication. Surf Coat Technol 2012;206:2035-56. 
82. Heimann RB. Thermal spraying of biomaterials. Surface Coatings Technol 
2006;201:2012-9. 
83. Surmenev RA, Surmeneva MA, Ivanova AA. Significance of calcium phosphate 
coatings for the enhancement of new bone osteogenesis – A review. Acta 
Biomater 2014:(in press). 
84. Bright DS, Clark HG, McCollum DE. Serum analysis and toxic effects of 
methylmethacrylate. Surgical Forum 1972; 23:455-457. 
85. Leeson MC, Lippitt SB. Thermal aspects of the use of polymethylmethacrylate in 
large metaphyseal defects in bone: A clinical review and laboratory study. Clin 
Orthop Relat Res 1993:239-45. 
86. Topoleski LDT, Ducheyne P, Cuckler JM. A fractographic analysis of in vivo 
poly(methyl methalcrylate) bone cement failure mechanisms. J Biomed Mater Res 
1990;24:135-54. 
87. Berlemann U, Ferguson SJ, Nolte LP, Hein PF. Adjacent vertebral failure after 
vertebroplasty - A biomechanical investigation. J Bone Joint Surg Br 
2002;84B:748-52. 
88. Lewis G. Injectable bone cements for use in vertebroplasty and kyphoplasty: 
State-of-the-art review. J Biomed Mater Res B Appl Biomater 2006;76:456-68. 
89. Urlings TAJ, Van Der Linden E. Elastoplasty: First experience in 12 patients. 
Cardiovasc Intervent Radiol 2013;36:479-83. 
35 
 
90. Blattert TR, Jestaedt L, Weckbach A. Suitability of a calcium phosphate cement 
in osteoporotic vertebral body fracture augmentation: a controlled, randomized, 
clinical trial of balloon kyphoplasty comparing calcium phosphate versus 
polymethylmethacrylate. Spine 2009;34:108-14. 
91. Piazzolla A, De Giorgi G, Solarino G. Vertebral body recollapse without trauma 
after kyphoplasty with calcium phosphate cement. Musculoskeletal Surgery 
2011;95:141-5. 
92. Boszczyk B. Prospective study of standalone balloon kyphoplasty with calcium 
phosphate cement augmentation in traumatic fractures (G. Maestretti et al.). Eur 
Spine J 2007;16:611. 
93. Maestretti G, Cremer C, Otten P, Jakob RP. Prospective study of standalone 
balloon kyphoplasty with calcium phosphate cement augmentation in traumatic 
fractures. European Spine Journal 2007;16:601-10. 
94. Bernards CM, Chapman JR, Mirza SK. Lethality of embolized norian bone 
cement varies with the time between mixing and embolization.  50th Annual 
Meeting of the Orthopaedic Research Society. San Fransisco2004. p. 0254. 
95.  Krebs J, Aebli N, Goss BG, Sugiyama S, Bardyn T, Boecken I, et al. 
Cardiovascular changes after pulmonary embolism from injecting calcium 
phosphate cement. J Biomed Mater Res B Appl Biomater 2007;82:526-32. 
96.  Dressel S, Jarvers JSG, Josten C, Blattert TR. Percutaneous balloon kyphoplasty 
in osteoporotic vertebral body fracture with a calcium aluminate ceramic 
(Xeraspine©). European Musculoskeletal Review 2012;7:209-12. 
97. Rauschmann M, Vogl T, Verheyden A, Pflugmacher R, Werba T, Schmidt S, et 
al. Bioceramic vertebral augmentation with a calcium sulphate/hydroxyapatite 
composite (Cerament™ SpineSupport) in vertebral compression fractures due to 
osteoporosis. European Spine Journal 2010;19:887-92. 
98. Masala S, Nano G, Marcia S, Muto M, Fucci FPM, Simonetti G. Osteoporotic 
vertebral compression fractures augmentation by injectable partly resorbable 
ceramic bone substitute (Cerament™|SPINE SUPPORT): A prospective 
nonrandomized study. Neuroradiology 2012;54:589-96. 
99. Bai B, Kummer FJ, Spivak J. Augmentation of anterior vertebral body screw 




100. Bohner M, Lemaitre J, Cordey J, Gogolewski S, Ring TA, Perren SM. Potential 
use of biodegradable bone cement in bone surgery: holding strength of screws in 
reinforced osteoporotic bone. Orthopaedic Transactions 1992;16:401-2. 
101. Mermelstein LE, Chow LC, Friedman C, Crisco Iii JJ. The Reinforcement of 
Cancellous Bone Screws with Calcium Phosphate Cement. Journal of Orthopaedic 
Trauma 1996;10:15-20. 
102. Stankewich CJ, Swiontkowski MF, Tencer AF, Yetkinler DN, Poser RD. 
Augmentation of femoral neck fracture fixation with an injectable calcium-
phosphate bone mineral cement. Journal of Orthopaedic Research 1996;14:786-
93. 
103. Larsson S, Stadelmann VA, Arnoldi J, Behrens M, Hess B, Procter P, et al. 
Injectable calcium phosphate cement for augmentation around cancellous bone 
screws. In vivo biomechanical studies. Journal of Biomechanics 2012;45:1156-60. 
104. Stadelmann VA, Bretton E, Terrier A, Procter P, Pioletti DP. Calcium phosphate 
cement augmentation of cancellous bone screws can compensate for the absence 
of cortical fixation. Journal of Biomechanics 2010;43:2869-74. 
105. Vallet-Regí M, Colilla M, Izquierdo-Barba I. Bioactive mesoporous silicas as 
controlled delivery systems: Aplication in bonetissue regeneration. J Biomed 
Nanotechnol 2008;4:1-15. 
106. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials 
2000; 2529-43. 
107. Stevens, MM, George, J. (2005). Exploring and Engineering the Cell Surface 
Interface. Science 2005; 310: 1135-38. 
108. Schieker M, Seitz H, Drosse I, Seitz S, Mutschler W. Biomaterials as scaffolds for 
bone tissue engineering. Eur J Trauma 2006;32:114-24. 
109. Kruyt MC, de Bruijn JD, Wilson CE, et al. Viable osteogenic cells are obligatory 
for tissue-engineered ectopic bone formation in goats. Tissue Eng 2003;9:327–36. 
110. Dorozhkin SV, Epple M. Biological and medical significance of calcium 
phosphates. Angew Chem Int Ed 2002;41:3130-46. 
111. Vallet-Regí M, González-Calbet JM. Calcium phosphates as substitution of bone 
tissues. Progr Solid State Chem 2004;32:1-31. 




113. Weiner S, Wagner HD. The material bone: structure-mechanical function 
relations. Annu Rev Mater Sci 1998;28:271-9. 
114. Tadic D, Epple M. A thorough physicochemical characterisation of 14 calcium 
phosphate-based bone substitution materials in comparison to natural bone. 
Biomaterials 2004;25:987-94. 
115. Weiss P, Obadia L, Magne D, Bourges X, Rau C, Weitkamp T, et al. Synchrotron 
X-ray microtomography (on a micron scale) provides three-dimensional imaging 
representation of bone ingrowth in calcium phosphate biomaterials. Biomaterials 
2003;24:4591-601. 
116. Schilling AF, Linhart W, Filke S, Gebauer M, Schinke T, Rueger JM, et al. 
Resorbability of bone substitute biomaterials by human osteoclasts. Biomaterials 
2004;25:3963-72. 
117. Detsch R, Hagmeyer D, Neumann M, Schaefer S, Vortkamp A, Wuelling M, et al. 
The resorption of nanocrystalline calcium phosphates by osteoclast-like cells. 
Acta Biomater 2010;6:3223-33. 
118. Xynos ID, Hukkanen MVJ,  Batten JJ, Buttery LD, Hench LL, Polak JM. 
Bioglass (R) 45S5 stimulates osteoblast turnover and enhances bone formation in 
vitro: Implications and applications for bone tissue engineering. Calcified Tissue 
Int 2000; 67:321-329. 
119. Han P, Wu C, Xiao Y. The effect of silicate ions on proliferation, osteogenic 
differentiation and cell signaling pathways (WNT and SHH) of bone marrow 
stromal cells. Biomater Sci 2013; 1: 379-392. 
120. Aguirre A, González A, Planell JA, Engel E. Extracellular calcium modulates in 
vitro bone marrow-derived Flk-1+ CD34+ progenitor cell chemotaxis and 
differentiation through a calcium-sensing receptor. Biochem Biophys Res Comm 
2010; 393: 156–161. 
121. Hench LL. Genetic design of bioactive glass, J. Eur Ceram Soc 2009;29 :1257–
1265. 
122. Rahaman MN, Day DE, Bal BS, Fu Q, Jung SB, Bonewald LF, Tomsia AP. 
Bioactive glass in tissue engineering, Acta Biomater 2011; 7: 2355-2373. 
123. Xynos ID, Edgar AJ, Buttery LDK, Hench LL, Polak JM. Gene-expression 
profiling of human osteoblasts following treatment with the ionic products of 
Bioglass® 45S5 dissolution. J Biomed Mater Res 2001; 55: 151-157. 
38 
 
124. Gorustovich AA, Roether JA, Boccaccini AR. Effect of Bioactive Glasses on 
Angiogenesis: In-vitro and In-vivo Evidence. A Review. Tissue Eng. Part B 
2010;16 199-207. 
125. Hench LL. Genetic design of bioactive glass, J. Eur Ceram Soc 2009;29 :1257–
1265. 
126. Navarro M, Ginebra MP, Planell JA. Cellular response to calcium phosphate 
glasses with controlled solubility. J Biomed Mater Res 2003; 67A: 1009-1015. 
127. Charles-Harris M, Koch M, Navarro M, Lacroix D, Engel E, Planell JA. A 
PLA/calcium phosphate degradable composite material for bone tissue 
engineering: an in vitro study. J Mater Sci: Mater Med, 2008;19:1503–1513. 
128. Navarro M, Sanzana ES, Planell JA, Ginebra MP, Torres PA. In Vivo behavior of 
calcium phosphate glasses with controlled solubility. Key Engineering Materials 
200;5 284-286: 893-896. 
129. Gentleman E, Fredholm YC, Jell G, Lotfibakhshaiesh N, O'Donnell MD, Hill RG, 
et al. The effects of strontium-substituted bioactive glasses on osteoblasts and 
osteoclasts in vitro. Biomaterials 2010; 31: 3949-3956. 
130. Teofilo JM, Brentegani LG, Lamano-Carvalho TL. Bone healing in osteoporotic 
female rats following intra-alveolar grafting of bioactive glass. Archives Oral 
Biol. 2004; 49: 755-762. 
131. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew 
Chem Int Ed 2007;46:7548-7558. 
132. Schliephake H, Weich HA, Dullin C, Gruber R, Frahse S. Mandibular bone repair 
by implantation of rhBMP-2 in a slow release carrier or polylactic acid - An 
experimental study in rats. Biomaterials 2008;29:103-110. 
133. Devescovi V, Leonardi E, Ciapetti G, Cenni E. Growth factors in bone repair. 
Chir Organi Mov 2008;92:161-168. 
134. Lissenberg-Thunnissen SN, de Gorter DJJ, Sier CFM, Schipper IB. Use and 
efficacy of bone morphogenetic proteins in fracture healing. Int Orthop 
2011;35:1271-1280. 
135. Wernike E, Montjovent MO, Liu Y, Wismeijer D, Hunziker EB, Siebenrock KA, 
et al. VEGF incorporated into calcium phosphate ceramics promotes 
vascularisation and bone formation in vivo. Eur Cells Mater 2010;19:30-40. 
39 
 
136. Lode A, Wolf-Brandstetter C, Reinstorf A, Bernhardt A, Koenig U, Pompe W, et 
al. Calcium phosphate bone cements, functionalized with VEGF: release kinetics 
and biological activity. J Biomed Mater Res 2007;81A:474-483. 
137. Evans CH. Gene therapy for bone healing. Exp Rev Molec Med 2010 23;12:e18. 
138. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 
2007;117:2083-2086. 
139.  Yi Y, Hahm SH, Lee KH. Retroviral gene therapy: Safety issues and possible 
solutions. Curr Gene Therapy 2005;5: 25-35. 
140. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into 
cells. Angew Chem Int Ed 2008;47:1382-1395. 
141. Guo X, Huang L. Recent advances in nonviral vectors for gene delivery. Acc 
Chem Res 2012;45:971-979. 
142. Wegman F, Bijenhof A, Schuijff L, Oner FC, Dhert WJA, Alblas J. Osteogenic 
differentiation as a result of BMP-2 plasmid DNA based gene therapy in vitro and 
in vivo. Eur Cell Mater 2011;21:230-242. 
143.  Zhang C, Wang KZ, Qiang H, Tang YL, Li QA, Li MA, et al. Angiopoiesis and 
bone regeneration via co-expression of the hVEGF and hBMP genes from an 
adeno-associated viral vector in vitro and in vivo. Acta Pharmacol Sin 
2010;31:821-830. 
144. Krebs MD, Salter E, Chen E, Sutter KA, Alsberg E. Calcium phosphate-DNA 
nanoparticle gene delivery from alginate hydrogels induces in vivo osteogenesis. J 
Biomed Mater Res A 2010;92A:1131-1138. 
145. Keeney M, van den Beucken JJJP, van der Kraan PM, Jansen JA, Pandit A. The 
ability of a collagen/calcium phosphate scaffold to act as its own vector for gene 
delivery and to promote bone formation via transfection with VEGF165. 
Biomaterials 2010;31:2893-2902. 
146. Cheang TY, Wang SM, Hu ZJ, Xing ZH, Chang GQ, Yao C, et al. Calcium 
carbonate/CaIP6 nanocomposite particles as gene delivery vehicles for human 
vascular smooth muscle cells. J Mater Chem 2010;20:8050-8055. 
147. Chernousova S, Klesing J, Soklakova N, Epple M. A genetically active nano-
calcium phosphate paste for bone substitution, encoding the formation of BMP-7 
and VEGF-A. RSC Adv 2013:(in press). 
40 
 
148. Liu H, Webster TJ. Mechanical properties of dispersed ceramic nanoparticles in 
polymer composites for orthopedic applications. Int J Nanomedicine 2010;5:299-
313. 
149. Dunlop JWC, Fratzl P. Biological composites. Ann Rev Mater Res 2010;40:1-24. 
150. Weiner S, Wagner HD. The material bone: structure-mechanical function 
relations. Annu Rev Mater Sci 1998;28:271-98. 
151. Nikolov S, Petrov M, Lymperakis L, Friak M, Sachs C, Fabritius HO, et al. 
Revealing the design principles of high-performance biological composites using 
ab initio and multiscale simulations: The example of lobster cuticle. Adv Mater 
2010;22:519. 
152. Kurreck J. RNA Interference: From basic research to therapeutic applications. 
Angew Chem Int Ed 2009;48:1378-1398. 
153. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of 
small interfering RNA. Biomaterials 2012;33:7138-7150. 
154. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits 
of nanosystems. Nanomedicine 2009;5:8-20. 
155. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev 
Genet 2009;10(2):94-108. 
156. Laroui H, Theiss AL, Yan Y, Dalmasso G, Nguyen HTT, Sitaraman SV, et al. 
Functional TNF-a gene silencing mediated by polyethyleneimine/TNF-a siRNA 
nanocomplexes in inflamed colon. Biomaterials 2011;32:1218-1228. 
157. Zhang X, Kovtun A, Mendoza-Palomares C, Oulad-Abdelghani M, Facca S, 
Fioretti F, et al. SiRNA-loaded multi-shell nanoparticles incorporated into a 
multilayered film as a reservoir for gene silencing. Biomaterials 2010;31:6013-
6018. 
158. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and 
Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 
14:285:785-95. 
159. Arvidson K, Abdallah BM, Applegate LA, Nicola Baldini N, Cenni E, Gomez-
Barrena E, Granchi D, Kassem M, Konttinen T, Mustafa K, Pioletti DP, Sillat T, 




160. Gómez-Barrena E, Rosset P, Muller I, Giordano R, Bunu C, Laroylle P, Konttinen 
YT, Luyten FT. Bone regeneration: stem cell therapies and clinical studies in 
orthopaedics and traumatology. J Cell Mol Med. 2011;15:1266-1286. 
161. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-
marrow grafting for nonunions. Influence of the number and concentration of 
progenitor cells. J Bone Joint Surg Am 2005; 87 1430-1437. 
162. Jakob F, Ebert R, Ignatius A, Matsushita T, Watanabe Y, Groll J et al. Bone tissue 
engineering in osteoporosis. Maturitas 2013; 75: 118-124. 
163. Bohner M, Lemaitre J. Can bioactivity be tested in vitro with SBF solution? 
Biomaterials 2009; 30: 2175-2179. 
164. Pan H, Zhao X, Darvell BW, Lu WW. Apatite-formation ability – Predictor of 
“bioactivity”?. Acta Biomaterialia 2010; 6: 4181-4188. 
165. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH et 
al. A Randomized Controlled Trial of Vertebroplasty for Osteoporotic Spine 
Fractures. N Engl J Med 2009; 361: 69-579. 
166. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, et al. A 
randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N 









Figure 1. Three trajectories of aging, with a differential risk for disability. 
Figure 2. The path from robustness towards frailty and disability: factors, biomarkers 
and modulators. 
Figure 3. Displaced intracapsular fracture (left) and trochanteric fracture (right). 
Figure 4. Osteoporotic vertebral fractures in T12 y L4 . Vertebroplasty in T12 and 
reduction and fixation with cannulated screws and cement in L4. 
Figure 5. Osteoporotic vertebral fractures treatment .Fixation with cannulated screws  
and cement 
Figure 6. DNA-loaded calcium phosphate nanorods which are able to induce the 
formation of BMP and VEGF.  
Figure 7. FDA pre-market approvals (PMAs) and pre-market notifications (510k) over 
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